Mark A Socinski MD

Oncology•Orlando, FL

Physician

Join to View Full Profile

2501 N Orange AveSte 689Orlando, FL 32804
Phone+1 407-303-2024
Fax+1 407-303-2038

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1989
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1986
University of Vermont College of MedicineClass of 1984

Certifications & Licensure

FL State Medical License 2016 - 2026
NC State Medical License 1995 - 2017
PA State Medical License 2011 - 2016
VT State Medical License 1988 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 2
BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Nov 01
Unknown status
Phase 2
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer Start of enrollment: 2005 May 31
Completed
Phase 2
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC Start of enrollment: 2004 May 01
Completed
Phase 2
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 Nov 01
Completed
Phase 3
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Immunization of Patients With Non Small Cell Lung Cancer (NSCLC) Start of enrollment: 2008 Dec 01
Terminated
Phase 1
Computed Tomography (CT) Perfusion Imaging of Lung Cancer Start of enrollment: 2009 Jun 01
Terminated
Not Applicable
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab Start of enrollment: 2010 Dec 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Start of enrollment: 2014 Apr 01
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Start of enrollment: 2019 Feb 01
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.
Frédérique Penault-Llorca, Mark A Socinski
The Oncologist. 2025-03-10
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial.
Yuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, Kenneth D Westover, Jonathan E Dowell
International Journal of Radiation Oncology, Biology, Physics. 2025-02-06
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
Dylan Fortman, Hong Wang, Robert VanderWeele, Terry Evans, James G Herman
Clinical Lung Cancer. 2025-01-01

Journal Articles

Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Robert M Jotte, Mark A Socinski, The New England Journal of Medicine
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Liza C Villaruz, Mark A Socinski, Molecular Diagnosis & Therapy

Lectures

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).
2019 ASCO Annual Meeting - 6/1/2019
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung ...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) bevacizumab (bev) vs chemo + bev in 1L nonsquamou...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Expanding Targets in Lung Cancer
Physicians' Education Resource, LLC, Chicago, Illinois - 6/2/2013
Join now to see all

Press Mentions

Low-Grade Immune-Related Adverse Events Linked to Prolonged Survival in NSCLCJune 5th, 2021
AdventHealth Sees Number of Hospitalized Patients DropFebruary 4th, 2021
AdventHealth Central Florida Asks for 40K Vaccines from State, Gets 500February 4th, 2021
Join now to see all